Global Hereditary Angioedema Treatment Market
Hereditary angioedema is an inherited condition characterized by re-occurant severe swelling. It affects arms, face, legs, airway and intestinal tract commonly. Having low level of C1 inhibitor, which is a protein that leads to excess activation of bradykinin which is a primary reason for angioedema. There are three types of hereditary angioedema Type-I, Type-II and Type-III. Type-I is characterised by low levels of C-1 inhibitor whereas Type -II characterised by normal or high levels of C-1 inhibitor. Type-III pathology is unknown. Usually symptoms will begin from puberty but may be seen even earlier. Minor trauma or stress may trigger the attack, however, swelling often occurs without a known trigger. Angioedema occurs in intestinal tract may lead to severe abdominal pain, nausea, and vomiting. Swelling in airway can obstruct passage of air and may lead to life threatening condition.
Hereditary Angioedema Treatment Market Outlook
Global hereditary angioedema treatment market is mainly driven by increase in R&D to treat angioedema. In addition, increase in prevalence and promising pipeline are expected to boost the hereditary angioedema treatment market. Furthermore, change in lifestyle, improved reimbursement infrastructure, and healthcare spending are expected to bolster the hereditary angioedema drugs market. However, high cost of prophylaxis and misdiagnosis of the condition are expected to hinder the hereditary angioedema drugs market during the forecast period.
Global Hereditary angioedema treatment market has been segmented based on type, drug class, and distribution channel
Base on type, hereditary angioedema treatment market is segmented into
Based on drug class, hereditary angioedema treatment market is segmented into
- C1 esterase inhibitors
- Plasma kallikrein inhibitors (Ecallantide)
- Bradykinin receptor antagonists (Icatibant)
- Autoimmune drugs
- Blood protein controllers
- Antifibrinolytic agents
Based on distribution channel, hereditary angioedema treatment market is segmented into
- Hospital Pharmacies
- Retail Pharmacies
Hereditary angioedema drugs market has expected to show healthy growth rate during forecast period. The market has many promising pipeline drugs and prophylaxis to treat hereditary angioedema. For instance, BioCryst Pharmaceuticals is in the process of developing a lead molecule known as BCX7353 to prevent an angioedema that attacks especially the patients suffering from hereditary angioedema and it has completed phase-II clinical trials. BioCryst pharmaceuticals received initial regulatory approvals in Europe to initiate the ZENITH-1 (clinical trail to study BCX7353) exploratory clinical trial in 2017. Shire plc is also conducting a post marketing investigation of drug Firazyr in countries where it is approved for hereditary angioedema attacks. Collaborations and acquisitions are key market strategies adopted by the market players. Companies also collaborating with research and non-profit organizations for better outcomes in treatment. For instance, in April 2017, PatientsLikeMe, a patient network and real-time research platform and Shire plc have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of patient health and disease. Licensing is also a key strategy in hereditary drugs market. For instance, in August 2016, Pharming Group NV, acquired back all North American commercialization rights to ruconest from Valeant Pharmaceuticals International, Inc.
Geographically global hereditary angioedema treatment market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to grow at significant growth rate due to lifestyle changes, increase in prevalence and growth in the diagnosis of hereditary angioedema in U.S. region. According to WHO, incidence rate of HAE is 1/10,000–50,000 people in United States and Canada in 2015 and Mortality rates are estimated as 15–33%. Asia-Pacific hereditary angioedema treatment market is expected to be fastest growing owing to increase in awareness about the disease conditions, developing healthcare infrastructure and lifestyle changes.
Some of the players in global hereditary angioedema drugs market are BioCryst Pharmaceuticals, Inc. (U.S), CSL Limited (Australia), Pharming Group NV (Netherlands), Salix Pharmaceuticals (U.S), and Shire (Republic of Ireland) to name a few.
- In June 2017, CSL Behring received U.S. FDA approval for its HAEGARDA(C1 Esterase Inhibitor Subcutaneous [Human]), a novel subcutaneous therapy by routine prophylaxis to treat hereditary angioedema.
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario